Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis

The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. Howeve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Renal failure Jg. 44; H. 1; S. 862 - 880
Hauptverfasser: Dai, Yali, Quan, Jingjing, Xiong, Lianlian, Luo, Yanfang, Yi, Bin
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Taylor & Francis 01.12.2022
Taylor & Francis Ltd
Taylor & Francis Group
Schlagworte:
Blood Glucose - metabolism
C-reactive protein
C-Reactive Protein - metabolism
Cholesterol
Cholesterol, LDL
Clinical Study
Clinical trials
Creatinine
Cystatin C
Diabetes
Diabetes Mellitus
diabetic kidney disease
Diabetic Nephropathies - metabolism
Diabetic Nephropathies - therapy
Glucose
Glucose - metabolism
glucose and lipid metabolism
Glutathione
Hemoglobin
High density lipoprotein
Homeostasis
Humans
Inflammation
Inflammation - metabolism
Insulin
Insulin Resistance
Kidney - metabolism
Kidney diseases
Lipid metabolism
Lipids
Meta-analysis
Metabolism
Nitric oxide
Oxidative Stress
Probiotics
Probiotics - therapeutic use
Renal function
Statistical analysis
Triglycerides
diabetic kidney disease
Probiotics
inflammation
glucose and lipid metabolism
meta-analysis
renal function
oxidative stress
ISSN:0886-022X, 1525-6049, 1525-6049
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD via meta-analysis. PubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively. Ten trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = −0.17 mg/dL; 95%CI = −0.29, −0.05; p = 0.004], blood urea nitrogen (BUN) [WMD = −1.36 mg/dL; 95%CI = −2.20, −0.52; p = 0.001], cystatin C (Cys C) [WMD = −29.50 ng/mL; 95%CI = −32.82, −26.18; p < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = −16.05 mg/g; 95%CI = −27.12, −4.99; p = 0.004] and natrium (Na) [WMD = −0.94 mmol/L; 95%CI = −1.82, −0.05; p = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day. Our analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.
AbstractList AimsThe role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD via meta-analysis.MethodsPubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively.ResultsTen trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = −0.17 mg/dL; 95%CI = −0.29, −0.05; p = 0.004], blood urea nitrogen (BUN) [WMD = −1.36 mg/dL; 95%CI = −2.20, −0.52; p = 0.001], cystatin C (Cys C) [WMD = −29.50 ng/mL; 95%CI = −32.82, −26.18; p < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = −16.05 mg/g; 95%CI = −27.12, −4.99; p = 0.004] and natrium (Na) [WMD = −0.94 mmol/L; 95%CI = −1.82, −0.05; p = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day.ConclusionsOur analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.
The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD via meta-analysis. PubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively. Ten trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = −0.17 mg/dL; 95%CI = −0.29, −0.05; p = 0.004], blood urea nitrogen (BUN) [WMD = −1.36 mg/dL; 95%CI = −2.20, −0.52; p = 0.001], cystatin C (Cys C) [WMD = −29.50 ng/mL; 95%CI = −32.82, −26.18; p < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = −16.05 mg/g; 95%CI = −27.12, −4.99; p = 0.004] and natrium (Na) [WMD = −0.94 mmol/L; 95%CI = −1.82, −0.05; p = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day. Our analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.
Aims The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD via meta-analysis.Methods PubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively.Results Ten trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = −0.17 mg/dL; 95%CI = −0.29, −0.05; p = 0.004], blood urea nitrogen (BUN) [WMD = −1.36 mg/dL; 95%CI = −2.20, −0.52; p = 0.001], cystatin C (Cys C) [WMD = −29.50 ng/mL; 95%CI = −32.82, −26.18; p < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = −16.05 mg/g; 95%CI = −27.12, −4.99; p = 0.004] and natrium (Na) [WMD = −0.94 mmol/L; 95%CI = −1.82, −0.05; p = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day.Conclusions Our analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.
The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD meta-analysis. PubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively. Ten trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = -0.17 mg/dL; 95%CI = -0.29, -0.05;  = 0.004], blood urea nitrogen (BUN) [WMD = -1.36 mg/dL; 95%CI = -2.20, -0.52;  = 0.001], cystatin C (Cys C) [WMD = -29.50 ng/mL; 95%CI = -32.82, -26.18;  < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = -16.05 mg/g; 95%CI = -27.12, -4.99;  = 0.004] and natrium (Na) [WMD = -0.94 mmol/L; 95%CI = -1.82, -0.05;  = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day. Our analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.
The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD via meta-analysis.AIMSThe role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics, which are widely used to modulate biomarkers of renal function, glucose, lipids, inflammation and oxidative stress in patients with DKD. However, their findings are controversial. This study aimed to systematically evaluate the impact of probiotics on patients with DKD via meta-analysis.PubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively.METHODSPubMed, The Cochrane Library, Web of Science, Scopus, Embase, China National Knowledge Infrastructure, Chinese Wanfang Database and Chinese VIP Database were searched for relevant studies from the establishment of these databases to September 2021. The pooled results evaluated the impact of probiotics on renal function, glucose, lipids, inflammation and oxidative stress indicators in patients with DKD. Additionally, subgroup analysis was performed based on intervention duration, probiotic dose and probiotic consumption patterns, respectively.Ten trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = -0.17 mg/dL; 95%CI = -0.29, -0.05; p = 0.004], blood urea nitrogen (BUN) [WMD = -1.36 mg/dL; 95%CI = -2.20, -0.52; p = 0.001], cystatin C (Cys C) [WMD = -29.50 ng/mL; 95%CI = -32.82, -26.18; p < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = -16.05 mg/g; 95%CI = -27.12, -4.99; p = 0.004] and natrium (Na) [WMD = -0.94 mmol/L; 95%CI = -1.82, -0.05; p = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day.RESULTSTen trials that included 552 participants were identified for analysis. Compared with the controls, probiotics significantly decreased serum creatinine (Scr) [WMD = -0.17 mg/dL; 95%CI = -0.29, -0.05; p = 0.004], blood urea nitrogen (BUN) [WMD = -1.36 mg/dL; 95%CI = -2.20, -0.52; p = 0.001], cystatin C (Cys C) [WMD = -29.50 ng/mL; 95%CI = -32.82, -26.18; p < 0.00001], urinary albumin/creatinine ratio (UACR) [WMD = -16.05 mg/g; 95%CI = -27.12, -4.99; p = 0.004] and natrium (Na) [WMD = -0.94 mmol/L; 95%CI = -1.82, -0.05; p = 0.04] in patients with DKD. Enhanced glycemic control was observed in patients with DKD receiving probiotics compared with controls, as demonstrated by reduced levels of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), homeostasis model of assessment-estimated insulin resistance (HOMA-IR), and increased quantitative insulin sensitivity check index (QUICKI). Probiotics affected lipid metabolism parameters with decreasing triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) levels in patients with DKD. Probiotics could also could improve inflammation and oxidative stress by decreasing high-sensitivity C-reactive protein (hs-CRP), plasma malondialdehyde (MDA), total antioxidant capacity (TAC), glutathione (GSH) and nitric oxide (NO). Additionally, subgroup analysis showed that those who received multiple species probiotics had a statistically significant difference in BUN, FPG, HOMA-IR, high-density lipoprotein cholesterol (HDL-c), MDA, TAC, and NO. Meanwhile, Scr, LDL-c, HDL-c, MDA, and TAC were ameliorated when the intervention duration was more than eight weeks and BUN, FPG, HOMA-IR, and MDA were improved when the probiotic dose was greater than four billion CFU/day.Our analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.CONCLUSIONSOur analysis revealed that probiotics could delay the progression of renal function injury, improve glucose and lipid metabolism, and reduce inflammation and oxidative stress in patients with DKD. Subgroup analysis showed that intervention duration, probiotic dose and probiotic consumption patterns had an effect of probiotics on outcomes.
Author Yi, Bin
Luo, Yanfang
Dai, Yali
Quan, Jingjing
Xiong, Lianlian
Author_xml – sequence: 1
  givenname: Yali
  surname: Dai
  fullname: Dai, Yali
  organization: Department of Nephrology, Yueyang People's Hospital, Yueyang Hospital affiliated to Hunan Normal University
– sequence: 2
  givenname: Jingjing
  surname: Quan
  fullname: Quan, Jingjing
  organization: Department of Nephrology, Third Xiangya Hospital, Central South University
– sequence: 3
  givenname: Lianlian
  surname: Xiong
  fullname: Xiong, Lianlian
  organization: Department of Nephrology, Third Xiangya Hospital, Central South University
– sequence: 4
  givenname: Yanfang
  surname: Luo
  fullname: Luo, Yanfang
  organization: Department of Nephrology, Third Xiangya Hospital, Central South University
– sequence: 5
  givenname: Bin
  surname: Yi
  fullname: Yi, Bin
  organization: Department of Nephrology, Third Xiangya Hospital, Central South University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35611435$$D View this record in MEDLINE/PubMed
BookMark eNqFks1u1DAUhSNURKeFRwBZYsNipthO7CQgIVDFT6VKsACJnXVj3wweEntqJ1PmSXhdnJlpRbuAjS3b53z32j4n2ZHzDrPsKaNnjFb0Ja0qSTn_fsbTmIayFpw_yGZMcLGQtKiPstmkWUyi4-wkxhWlTFQlf5Qd50IyVuRilv3-Enxj_WB1JLZfB79BEtBBR9rR6cF6NyfLbtQ-4px0dm1NnBPr2g76HqZjAs4Q_8uatEreOASMCeWIsdBg4pKf1jjcpnVEiPiKAInbOOBk16nWxuL1DtLjAAtIpbfRxsfZwxa6iE8O82n27cP7r-efFpefP16cv7tcaCH5sJBcl4bKwrSMIjUVllIUjSm5EaZGxALq0kBNdVuW1GhgVFItmobJBnLgbX6aXey5xsNKrYPtIWyVB6t2Gz4sFYTUaIdKmEZoyUuDNS9yySshkbeClbTROdR5Yr3Zs9Zj06PR6IYA3R3o3RNnf6il36iaiaKsZAK8OACCvxoxDqq3UWPXgUM_RsWlrAUVuZhqPb8nXfkxpMdLqrKi0_fWLKme_d3RbSs3_58EYi_QwccYsL2VMKqmnKmbnKkpZ-qQs-R7fc-n7bDLQ7qY7f7rfrt3pyD50MO1D51RA2w7H9oATtuo8n8j_gCbje8q
CitedBy_id crossref_primary_10_1007_s12602_025_10710_3
crossref_primary_10_1016_j_biopha_2025_118421
crossref_primary_10_3389_fmicb_2024_1361439
crossref_primary_10_3390_biom14081029
crossref_primary_10_33073_pjm_2024_025
crossref_primary_10_3390_ijms232314838
crossref_primary_10_1016_j_biopha_2023_114985
crossref_primary_10_1093_femsyr_foad041
crossref_primary_10_1155_2022_1668000
crossref_primary_10_3390_biomedicines11092480
crossref_primary_10_1038_s41598_025_93811_x
crossref_primary_10_1007_s40620_025_02212_w
crossref_primary_10_2174_0115701638349511250121114323
crossref_primary_10_1186_s10020_023_00745_z
crossref_primary_10_1007_s11033_024_10041_6
crossref_primary_10_1016_j_phrs_2022_106481
crossref_primary_10_2174_0109298673296482240426111529
crossref_primary_10_1080_0886022X_2025_2557019
crossref_primary_10_1016_j_bioorg_2024_107151
crossref_primary_10_1016_j_ijbiomac_2023_127907
crossref_primary_10_3390_biom13071086
crossref_primary_10_3389_fnut_2023_1155306
crossref_primary_10_1007_s10068_024_01775_x
crossref_primary_10_1080_10408398_2022_2117783
crossref_primary_10_3389_fimmu_2023_1113212
crossref_primary_10_1007_s00018_024_05532_5
crossref_primary_10_1016_j_nutres_2023_06_004
crossref_primary_10_1016_j_phrs_2022_106520
crossref_primary_10_1080_0886022X_2022_2152693
crossref_primary_10_1210_clinem_dgaf340
crossref_primary_10_5315_wjh_v10_i2_15
crossref_primary_10_1155_2023_8871677
crossref_primary_10_7759_cureus_55149
crossref_primary_10_1186_s12876_024_03562_8
crossref_primary_10_3390_livers4030032
crossref_primary_10_1016_j_ejphar_2025_177326
crossref_primary_10_1097_MD_0000000000042754
crossref_primary_10_3390_nu17132112
crossref_primary_10_3390_metabo13020306
crossref_primary_10_1002_jbt_70185
crossref_primary_10_1007_s44411_025_00208_3
crossref_primary_10_1007_s13668_024_00527_x
crossref_primary_10_1053_j_jrn_2025_03_008
crossref_primary_10_3389_fnut_2025_1552358
crossref_primary_10_1007_s10482_025_02141_5
crossref_primary_10_1016_j_diabres_2024_111726
crossref_primary_10_3390_ijms26041773
crossref_primary_10_1080_13880209_2024_2351946
crossref_primary_10_3390_ijms25021314
crossref_primary_10_3389_fmicb_2023_1121695
crossref_primary_10_3390_ijms251810051
crossref_primary_10_3389_fendo_2024_1385872
crossref_primary_10_3390_antiox12101894
crossref_primary_10_1007_s10787_023_01332_8
crossref_primary_10_1002_dmrr_3675
crossref_primary_10_1016_j_anifeedsci_2025_116368
crossref_primary_10_3233_JAD_220651
crossref_primary_10_1002_JPER_22_0721
crossref_primary_10_1155_jdr_4481506
crossref_primary_10_3389_fendo_2024_1364280
Cites_doi 10.1503/cmaj.060410
10.1039/C8FO00888D
10.1097/MCG.0000000000001064
10.1007/s40200-021-00765-8
10.2174/1871530321666210121154037
10.1097/MD.0000000000009166
10.1016/j.cofs.2020.01.003
10.3390/nu9050521
10.21037/atm.2019.01.61
10.1007/s11892-017-0841-z
10.1038/ki.2015.255
10.1210/er.2016-1122
10.1002/jcla.23650
10.1111/dom.12475
10.2174/1574884715666200303112753
10.1007/s00394-010-0166-z
10.1093/ajcn/71.3.674
10.1016/j.clnesp.2020.06.019
10.1111/j.1365-2672.2006.02963.x
10.1016/j.heliyon.2021.e05925
10.1089/bfm.2019.0301
10.1186/s12937-016-0127-3
10.1007/s12602-017-9325-3
10.1007/s11892-019-1133-6
10.1016/j.phrs.2019.02.016
10.1172/JCI28898
10.1166/mex.2021.1888
10.1007/s12602-018-9468-x
10.2217/clp.12.40
10.1016/j.ejphar.2020.173461
10.1155/2021/1497449
10.1016/j.kint.2016.09.040
10.1017/S0007114509993801
10.1080/0886022X.2020.1864404
10.1186/s12906-015-0952-5
10.1053/j.jrn.2017.04.004
10.1016/j.nut.2018.01.007
10.1016/j.numecd.2017.06.020
10.1038/ki.2012.345
10.1097/MNH.0b013e328358c8d5
10.1017/S0007114513003607
ContentType Journal Article
Copyright 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022
2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022
– notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1080/0886022X.2022.2079522
DatabaseName Taylor & Francis Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials Local Electronic Collection Information
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database


MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
– sequence: 4
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Y. Dai et al
EISSN 1525-6049
EndPage 880
ExternalDocumentID oai_doaj_org_article_5db5c627de924362856e2f5170bc3a93
PMC9154786
35611435
10_1080_0886022X_2022_2079522
2079522
Genre Research Article
Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
00X
0YH
123
29P
36B
4.4
53G
5RE
7X7
88E
8FI
8FJ
8G5
ABDBF
ABUWG
ACGEJ
ACGFS
ACUHS
ADBBV
ADCVX
ADRBQ
ADXPE
AENEX
AFKRA
AFKVX
AJWEG
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AQTUD
ARJSQ
AZQEC
BABNJ
BCNDV
BENPR
BLEHA
CCPQU
CS3
DWQXO
EAP
EBC
EBD
EBS
EMB
EMK
EMOBN
EPL
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
H13
HMCUK
HZ~
M1P
M2O
M4Z
O9-
P2P
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PROAC
PSQYO
RPM
SV3
TDBHL
TFDNU
TFL
TFW
TUS
UKHRP
V1S
~1N
AAYXX
AFFHD
CITATION
.GJ
5VS
AALIY
AAORF
AAPXX
ABWCV
AFLEI
AJVHN
AWYRJ
BPHCQ
BRMBE
CAG
CGR
COF
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
EJD
HYE
JENTW
M44
NPM
NUSFT
OK1
PQQKQ
QQXMO
ZGI
ZXP
3V.
7T5
7XB
8FK
H94
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c562t-62c7d064df10e0d8e7654bd72d5d9eee4a97da90cf770dca1060c5bb16ba3a2f3
IEDL.DBID BENPR
ISICitedReferencesCount 73
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000800051200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0886-022X
1525-6049
IngestDate Fri Oct 03 12:40:38 EDT 2025
Tue Nov 04 01:41:19 EST 2025
Thu Oct 02 10:19:26 EDT 2025
Tue Oct 07 06:58:45 EDT 2025
Wed Feb 19 02:26:09 EST 2025
Sat Nov 29 02:26:01 EST 2025
Tue Nov 18 22:38:06 EST 2025
Mon Oct 20 23:46:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords diabetic kidney disease
Probiotics
inflammation
glucose and lipid metabolism
meta-analysis
renal function
oxidative stress
Language English
License open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c562t-62c7d064df10e0d8e7654bd72d5d9eee4a97da90cf770dca1060c5bb16ba3a2f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.proquest.com/docview/2780611491?pq-origsite=%requestingapplication%
PMID 35611435
PQID 2780611491
PQPubID 3933335
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_5db5c627de924362856e2f5170bc3a93
informaworld_taylorfrancis_310_1080_0886022X_2022_2079522
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9154786
proquest_miscellaneous_2669505353
crossref_citationtrail_10_1080_0886022X_2022_2079522
pubmed_primary_35611435
crossref_primary_10_1080_0886022X_2022_2079522
proquest_journals_2780611491
PublicationCentury 2000
PublicationDate 2022-Dec
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-Dec
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
PublicationTitle Renal failure
PublicationTitleAlternate Ren Fail
PublicationYear 2022
Publisher Taylor & Francis
Taylor & Francis Ltd
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Ltd
– name: Taylor & Francis Group
References e_1_3_4_3_1
Opazo-Ríos L (e_1_3_4_2_1) 2020; 21
e_1_3_4_9_1
e_1_3_4_42_1
e_1_3_4_7_1
e_1_3_4_40_1
e_1_3_4_46_1
e_1_3_4_21_1
e_1_3_4_44_1
e_1_3_4_27_1
e_1_3_4_48_1
Abbasi B (e_1_3_4_23_1) 2017; 11
e_1_3_4_29_1
e_1_3_4_53_1
e_1_3_4_51_1
e_1_3_4_13_1
e_1_3_4_34_1
e_1_3_4_11_1
e_1_3_4_32_1
e_1_3_4_38_1
e_1_3_4_15_1
e_1_3_4_36_1
e_1_3_4_19_1
Miranda Alatriste PV (e_1_3_4_30_1) 2014; 29
e_1_3_4_4_1
Kinoshita A (e_1_3_4_50_1) 2015; 62
e_1_3_4_8_1
e_1_3_4_41_1
e_1_3_4_6_1
Ostadrahimi A (e_1_3_4_37_1) 2015; 44
e_1_3_4_24_1
e_1_3_4_45_1
e_1_3_4_22_1
e_1_3_4_43_1
e_1_3_4_28_1
e_1_3_4_49_1
e_1_3_4_26_1
e_1_3_4_47_1
Viera AJ (e_1_3_4_14_1) 2005; 37
Tang W (e_1_3_4_20_1) 2020; 32
e_1_3_4_31_1
e_1_3_4_52_1
Abbasi B (e_1_3_4_25_1) 2018; 20
e_1_3_4_12_1
e_1_3_4_35_1
e_1_3_4_10_1
e_1_3_4_33_1
Li R (e_1_3_4_5_1) 2013; 19
e_1_3_4_16_1
e_1_3_4_39_1
e_1_3_4_18_1
Kang DY (e_1_3_4_17_1) 2003; 3
References_xml – ident: e_1_3_4_16_1
  doi: 10.1503/cmaj.060410
– ident: e_1_3_4_18_1
  doi: 10.1039/C8FO00888D
– ident: e_1_3_4_39_1
  doi: 10.1097/MCG.0000000000001064
– ident: e_1_3_4_11_1
  doi: 10.1007/s40200-021-00765-8
– ident: e_1_3_4_13_1
  doi: 10.2174/1871530321666210121154037
– ident: e_1_3_4_47_1
  doi: 10.1097/MD.0000000000009166
– ident: e_1_3_4_6_1
  doi: 10.1016/j.cofs.2020.01.003
– ident: e_1_3_4_49_1
  doi: 10.3390/nu9050521
– volume: 62
  start-page: 966
  issue: 140
  year: 2015
  ident: e_1_3_4_50_1
  article-title: C-Reactive protein as a prognostic marker in patients with hepatocellular carcinoma
  publication-title: Hepatogastroenterology
– ident: e_1_3_4_40_1
  doi: 10.21037/atm.2019.01.61
– ident: e_1_3_4_34_1
  doi: 10.1007/s11892-017-0841-z
– ident: e_1_3_4_8_1
  doi: 10.1038/ki.2015.255
– volume: 21
  start-page: 862
  issue: 7
  year: 2020
  ident: e_1_3_4_2_1
  article-title: Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities
  publication-title: IJMS
– ident: e_1_3_4_15_1
– ident: e_1_3_4_44_1
  doi: 10.1210/er.2016-1122
– ident: e_1_3_4_19_1
  doi: 10.1002/jcla.23650
– ident: e_1_3_4_41_1
  doi: 10.1111/dom.12475
– ident: e_1_3_4_10_1
  doi: 10.2174/1574884715666200303112753
– volume: 37
  start-page: 360
  issue: 5
  year: 2005
  ident: e_1_3_4_14_1
  article-title: Understanding interobserver agreement: the kappa statistic
  publication-title: Fam Med
– ident: e_1_3_4_28_1
  doi: 10.1007/s00394-010-0166-z
– ident: e_1_3_4_43_1
  doi: 10.1093/ajcn/71.3.674
– ident: e_1_3_4_12_1
  doi: 10.1016/j.clnesp.2020.06.019
– ident: e_1_3_4_32_1
  doi: 10.1111/j.1365-2672.2006.02963.x
– ident: e_1_3_4_53_1
  doi: 10.1016/j.heliyon.2021.e05925
– ident: e_1_3_4_7_1
  doi: 10.1089/bfm.2019.0301
– ident: e_1_3_4_33_1
  doi: 10.1186/s12937-016-0127-3
– ident: e_1_3_4_24_1
  doi: 10.1007/s12602-017-9325-3
– ident: e_1_3_4_4_1
  doi: 10.1007/s11892-019-1133-6
– ident: e_1_3_4_52_1
  doi: 10.1016/j.phrs.2019.02.016
– ident: e_1_3_4_38_1
  doi: 10.1172/JCI28898
– ident: e_1_3_4_36_1
  doi: 10.1166/mex.2021.1888
– volume: 20
  start-page: 70
  issue: 2
  year: 2018
  ident: e_1_3_4_25_1
  article-title: Effects of probiotic soy milk on lipid panel in type 2 diabetic patients with nephropathy: a double-blind randomized clinical trial
  publication-title: Prog Nutr
– volume: 19
  start-page: 421
  issue: 5
  year: 2013
  ident: e_1_3_4_5_1
  article-title: Medical costs associated with type 2 diabetes complications and comorbidities
  publication-title: Am J Manag Care
– volume: 3
  start-page: 45
  issue: 1
  year: 2003
  ident: e_1_3_4_17_1
  article-title: Identification and treatment of publication bias in meta-analysis
  publication-title: Chin J Evid-Based Med
– ident: e_1_3_4_21_1
  doi: 10.1007/s12602-018-9468-x
– ident: e_1_3_4_42_1
  doi: 10.2217/clp.12.40
– ident: e_1_3_4_46_1
  doi: 10.1016/j.ejphar.2020.173461
– ident: e_1_3_4_3_1
  doi: 10.1155/2021/1497449
– ident: e_1_3_4_9_1
  doi: 10.1016/j.kint.2016.09.040
– ident: e_1_3_4_51_1
  doi: 10.1017/S0007114509993801
– ident: e_1_3_4_27_1
  doi: 10.1080/0886022X.2020.1864404
– ident: e_1_3_4_22_1
  doi: 10.1186/s12906-015-0952-5
– ident: e_1_3_4_26_1
  doi: 10.1053/j.jrn.2017.04.004
– ident: e_1_3_4_35_1
  doi: 10.1016/j.nut.2018.01.007
– ident: e_1_3_4_48_1
  doi: 10.1016/j.numecd.2017.06.020
– ident: e_1_3_4_29_1
  doi: 10.1038/ki.2012.345
– ident: e_1_3_4_31_1
  doi: 10.1097/MNH.0b013e328358c8d5
– volume: 32
  start-page: 570
  issue: 5
  year: 2020
  ident: e_1_3_4_20_1
  article-title: Effect of probiotics supplementation on the risk of disease progression in elderly diabetic nephropathy patients
  publication-title: Chin J Microecol
– volume: 44
  start-page: 228
  issue: 2
  year: 2015
  ident: e_1_3_4_37_1
  article-title: Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial
  publication-title: Iran J Public Health
– ident: e_1_3_4_45_1
  doi: 10.1017/S0007114513003607
– volume: 29
  start-page: 582
  issue: 3
  year: 2014
  ident: e_1_3_4_30_1
  article-title: Effect of probiotics on human blood urea levels in patients with chronic renal failure
  publication-title: Nutr Hosp
– volume: 11
  start-page: 36
  issue: 1
  year: 2017
  ident: e_1_3_4_23_1
  article-title: Kidney function improvement by soy milk containing Lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy: a double-blinded randomized controlled trial
  publication-title: Iran J Kidney Dis
SSID ssj0015872
Score 2.5506434
SecondaryResourceType review_article
Snippet The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of probiotics,...
AimsThe role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of...
Aims The role of probiotics in the management of diabetic kidney disease (DKD) has been shown. Several current trials are investigating the effect of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 862
SubjectTerms Blood Glucose - metabolism
C-reactive protein
C-Reactive Protein - metabolism
Cholesterol
Cholesterol, LDL
Clinical Study
Clinical trials
Creatinine
Cystatin C
Diabetes
Diabetes Mellitus
diabetic kidney disease
Diabetic Nephropathies - metabolism
Diabetic Nephropathies - therapy
Glucose
Glucose - metabolism
glucose and lipid metabolism
Glutathione
Hemoglobin
High density lipoprotein
Homeostasis
Humans
Inflammation
Inflammation - metabolism
Insulin
Insulin Resistance
Kidney - metabolism
Kidney diseases
Lipid metabolism
Lipids
Meta-analysis
Metabolism
Nitric oxide
Oxidative Stress
Probiotics
Probiotics - therapeutic use
Renal function
Statistical analysis
Triglycerides
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lj9MwEIAttEKIC-JNYEFG4thAYsdxzA0QKy6s9gBSb5ZfERFLumqzK_gl_F1mbKe0K6ReuCZ2E2fG9Yw98w0hr4xwRoEfUDZc2rKpfQVzjtsSFlvlpbSNMy4Wm5Cnp91yqc52Sn1hTFjCA6cP90Z4K1zLpA_gKXBM-GsD60UtK-u4UZHzCVbP7Ezl8wPRxbJNMIUwxJYt59wdpGp3WHaJLcE3ZJiJJZVgbG9VivD-a-jSfxmg1-Modxamk7vkTrYo6bs0knvkRhjvk1uf85n5A_L7LKKWEMdMh7iFEOg6YBdc01AuC5oD1xf0fLgY_GZB4aVAVVJaIzWjp6ufg4-McJqyS6AFTfu2g6PfBz-GXzQf9rylhv4FRNOUHBN_5EeYTGkyBuUh-Xry8cuHT2Uux1A6MJKmsmVOerBgfF9XofJdkK1orJfMC69CCI1R0htVuV7KyjsDzmblhLV1aw03rOePyNG4GsMTQnltegO2pwrcNgz3PYQJ0oKxalxTV7wgzSwO7TKrHEtmnOt6RppmKWqUos5SLMjrbbeLBOs41OE9ynrbGFnb8QJooM4aqA9pYEHUrqboKW619KkuiuYHXuB4Viud_zw2mskOrCxwXeuCvNzehmmPZzlmDKtLaNO2SiCbBx7_OGnhdhRcYG8uCiL39HNvmPt3xuFbRIurGvlu7dP_8V2ekds41BT7c0yOpvVleE5uuqtp2KxfxPn6B2heQPQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Taylor & Francis Journals Complete
  dbid: TFW
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQVSEuUN4LBRmJ4waSOI7XvRXEigtVD0XszfIrELVkq02K4Jfwd5mxndCtQD3AMYkn8Thjz4w98w0hLzW3WoIfkFVMmKwqXA5zjpkMlK10QpjKahuKTYijo8VqJY9TNGGfwirRh24iUERYq3Fya9OPEXGvYWLUoHpW4N2VmEslJBgRsAqD6scaBifLT9M5Al-E8k1IkSHJmMPzt7dsaacA4n8FwvRPhujVeMpLCmp55z-wtkduJ-uUHkZxuktu-O4eufkhnb_fJz-PA2wTQjvTNmxHeLrxSIL6Ef_xnKYg-Dk9a89b188pMAZiF1MkKfSMrr-3LuCN05ipAi1o3ANuLT1tXed_0HRwdEA1_Q02TWOiTXjJVz_oTCdIlQfk4_Ldydv3WSrtkFkwuIasLq1wYA25psh97hZe1LwyTpSOO-m9r7QUTsvcNkLkzmpwXHPLjSlqo5kuG_aQ7HTrzj8mlBW60WDHSs9MVeIeCtdeGDB8ta2KnM1INf5SZRPuOZbfOFPFCI-aBl3hoKs06DPyaiI7j8Af1xG8QXmZGiNud7ix3nxWaRlQ3Blu61I4D34vw_TV2pcNL0RuLNMSOisvS5sawrZNE2usKHZNB_ZH0VRpIepVKRZgsYEbXMzIi-kxLCF4LqQ7v76ANnUtOeL8wOcfRUmeuGAcqRmfEbEl41tsbj_p2i8BplwWiBVXP_kHlp6SW3gZw4f2yc6wufDPyK79NrT95nmY6r8AAnxSMw
  priority: 102
  providerName: Taylor & Francis
Title Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis
URI https://www.tandfonline.com/doi/abs/10.1080/0886022X.2022.2079522
https://www.ncbi.nlm.nih.gov/pubmed/35611435
https://www.proquest.com/docview/2780611491
https://www.proquest.com/docview/2669505353
https://pubmed.ncbi.nlm.nih.gov/PMC9154786
https://doaj.org/article/5db5c627de924362856e2f5170bc3a93
Volume 44
WOSCitedRecordID wos000800051200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: DOA
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: BENPR
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: 7X7
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: PIMPY
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Research Library
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: M2O
  dateStart: 20171101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/pqrl
  providerName: ProQuest
– providerCode: PRVAWR
  databaseName: Taylor & Francis Journals Complete
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: TFW
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
– providerCode: PRVAWR
  databaseName: Taylor & Francis Open Access
  customDbUrl:
  eissn: 1525-6049
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0015872
  issn: 0886-022X
  databaseCode: 0YH
  dateStart: 19870101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwELZYhxAv_B4URmUkHhtI7DiOeUEMrRoPLRUaonuKHNuBiJGUtkPwl_Dvcue43Toh9sCLpSR2Yiufz-fz3XeEPNfCaAX7gCjlsozSxMYw53gZwWKrrJRlarTxySbkZJLPZmoaDG7L4Fa5loleUNvWoI38JZM5LD2gzyev598jzBqFp6shhcYO2UWmsrRHdg8OJ9MPm3MEkfv0TTCV0NWWzdYxPMiunWP6JTaDPSLDiCypBGNbq5Mn8b9EYfo3RfSyP-WFBWp0-3-HdofcCqopfdNh6S655pp75MY4HL7fJ7-nnrMJeZ1p7W0Rji4cNsHFEX_wkAYP-CE9ree1XQ4pjAow18VHUt1Y2v6srScbp12YCtSgnQG4NvRrbRv3i4ZTo1dU03OmadpF2fiXfHMrHenAp_KAfBwdHr89ikJeh8iAtrWKMmakBVXIVknsYps7mYm0tJJZYZVzLtVKWq1iU0kZW6Nh1xobUZZJVmquWcX3SK9pG_eIUJ7oSoMSqxwvU4YGFKGdLEHr1SZNYt4n6fp_FiaQnmPujdMiWXOjBhgUCIMiwKBPXmyazTvWj6saHCBYNpWRtNvfaBefiyADCmFLYTImrYNNL8fY1cyxSiQyLg3XCjqrLkKtWHmbTdUlWCn4FR3YX2OrCFJoWZwDq0-ebR6D_MBDId249gzqZJkSSPIDn3_YwXgzCi6wNRd9IrcAvjXM7SdN_cVzlKsEieKyx__u1hNyEwfRuQftk95qceaekuvmx6peLgZkJz45glLOpC_zQZjeA285gXLM3sO96bvx9ASujkef_gB2CFha
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90thgJHgrYHEjuMaCSFu06Zt1R6G1Dfj2A5EjLS0HbBfwr_gN3KO43TrhNjTHnht7NR2zt3nfIeQJ0ZYo8APSHIuyyTPXAo8x8sElK1yUpa5NTY0m5DD4WA0Ursr5HdXC4NplZ1MDILajS3GyJ8zOQDVA_Z89mryLcGuUXi72rXQaMliyx_-AJdt9nLzHXzfp4ytv997u5HErgKJBV0_TwpmpQNF7Kos9akbeFmIvHSSOeGU9z43SjqjUltJmTprwGdKrSjLrCgNN6zi8N5z5DzIcYkpZHK0cPAyMQjNooBxMbGXjbqKIcTyHmCzJzYCj5Rh_ZdUgrElXRhaBpwATP2b2Xsye_OYOly_-r8d5DVyJRre9HXLKdfJim9ukIs7MbXgJvm1GxCpELWa1iHS4unU4xRU_Ui-fRrz-_t0v57UbtancIrAUW31JzWNo-OftQtQ6rQtwoERtA1v15Z-qV3jD2m8E3tBDT3C0aZtDVF4yVc_N4mJaDG3yIczOZbbZLUZN_4uoTwzlQETXXle5gzDQ8J4WYJNb2yepbxH8o5-tI2Q7thZZF9nHfJrJDuNZKcj2fXIs8W0SYtpctqEN0ici8EISR5-GE8_6SjhtHClsAWTzoNLz7Eyt_CsEplMS8uNgsWq46St5yEiVbXtYzQ_ZQFrHS3rKGNn-oiQe-Tx4jFIR7zyMo0fH8CYolACIYzg7--0bLPYBRc4m4sekUsMtbTN5SdN_TkgsKsMYfCKe_9e1iNyaWNvZ1tvbw637pPLuKE2EWqNrM6nB_4BuWC_z-vZ9GEQI5R8PGt2-wMrG67X
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgQau98GYpLGAkjg2bxHFcc-NVgYCqh0X0ZvkViFjSqs0i-CX8XWYcJ2xXoD3ANfYkHmfsmbFnviHkseZWS_ADkoIJkxSZS2HNMZOAspVOCFNYbUOxCTGbTRYLOY_RhJsYVok-dNUBRYS9Ghf3ylV9RNwhLIwSVM8CvLscc6mEBCPiIrkEpnOJ_tfR9ONwkcAnoX4TkiRI0yfx_O01W-opoPifwTD9kyV6NqDylIaaXv0PvF0jV6J5Sp918nSdXPDNDbL7Pl7A3yQ_5wG3CbGdaR3OIzxdeyRBBYk_eUxjFPyYHter2m3GFBgDuetyJCmMjC6_1y4AjtMuVQV60O4QuLb0S-0a_4PGm6OnVNPfaNO0y7QJL_nqW53oiKlyi3yYvjp68TqJtR0SCxZXm5S5FQ7MIVdlqU_dxIuSF8aJ3HEnvfeFlsJpmdpKiNRZDZ5rarkxWWk003nFbpOdZtn4O4SyTFcaDFnpmSlyPETh2gsDlq-2RZayESn6X6psBD7H-hvHKuvxUeOkK5x0FSd9RJ4MZKsO-eM8gucoL0NnBO4OD5brTyruA4o7w22ZC-fB8WWYv1r6vOKZSI1lWsJg5WlpU204t6m6IiuKnTOAg140VdyJNioXEzDZwA_ORuTR0Ax7CF4M6cYvT6BPWUqOQD_w-f1OkgcuGEdqxkdEbMn4FpvbLU39OeCUywzB4sq7_8DSQ7I7fzlV797M3t4je9jShRIdkJ12feLvk8v2W1tv1g_Cqv8F8aVVDw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Probiotics+improve+renal+function%2C+glucose%2C+lipids%2C+inflammation+and+oxidative+stress+in+diabetic+kidney+disease%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Renal+failure&rft.au=Dai%2C+Yali&rft.au=Quan%2C+Jingjing&rft.au=Xiong%2C+Lianlian&rft.au=Luo%2C+Yanfang&rft.date=2022-12-01&rft.pub=Taylor+%26+Francis+Ltd&rft.issn=0886-022X&rft.eissn=1525-6049&rft.volume=44&rft.issue=1&rft.spage=862&rft.epage=880&rft_id=info:doi/10.1080%2F0886022X.2022.2079522
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0886-022X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0886-022X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0886-022X&client=summon